Author Archives: admin

Hyper-targeting Oncologists

Whilst the importance of conferences such as ASCO and ASH are acknowledged this mantle is shared more than ever today.

ESMOs importance has grown significantly in recent years both in terms of size and diversity of audience as well as its reach as a global platform (e.g. more US healthcare professionals following ESMO online). In 2018, ESMO attracted nearly 28,000 attendees from 137 countries and over 3,000 submitted abstracts compared to 16,000 attendees from 127, and just over 2,000 submitted abstracts from the 2012 ESMO conference.

There has also been a noticeable rise in the importance of highly targeted disease-focused conferences such as EHA, IASLC, ICML, increased number of breakout meetings under the auspices of ASCO and ESMO (focusing on one cancer), and other similar scientific conferences with their increased importance as a platform for the dissemination of new data, meetings, exchange and reach to a global audience.

Hyper-targeting the right audience

With this in mind, biopharmaceutical companies need reliable agency partners with winning expertise and experience knowing what it takes to master these trends. In a highly competitive space where hyper-targeting is essential, MDoutlook provides clients with the right mix of agile assets, value solutions, and professional customer access to drive successful precision engagement with your most relevant customers in oncology, hematology, and rare diseases.

In a recent project, we measured the impact of our client’s new data announcements by interviewing oncologists in a rare disease area attending the International Congress on Malignant Lymphomas (ICML) in Lugano. The challenge was even greater due to the timing of the meeting, immediately following EHA and the need to engage oncologists based in the US and attending this highly focused European meeting.

Whether you are assessing the impact of data announcements or have another project in mind that requires hyper-targeting of your professional customers, we can enable your success by utilizing our proprietary assets and access to the world’s largest verified community of >120,000 treaters and experts in oncology, hematology, and rare diseases. This community is enriched through physician self-reported characteristics, and external adapters that are carefully and meaningfully applied through machine-learning and AI.

Meet us

We constantly deliver value to our clients by engaging the right professional customers to inform the clients’ business decisions and commercialization strategies of their assets in the right way throughout the product lifecycle.

Let’s take your next step together by arranging a meeting at your offices to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.

The treatment landscape for prostate cancer is changing

Cabazitaxel was presented as an option for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with docetaxel and an androgen signaling-targeted agent according to data presented at ESMO 2019.

The results showed a significant survival benefit for Cabazitaxel in third line over enzalutamide or abiraterone where patients had previously undergone treatment with one of the 2nd generation antiandrogens and docetaxel.

Impact of announcement

There was a general perception among prostate cancer ThoughtLeaders at ESMO 2019 that Cabazitaxel could become a new standard in mCRPC post-docetaxel and 2nd generation antiandrogen. Cabazitaxel is already widely available in many countries aiding the anticipated changes in treatment practices and guidelines. Contrary to current standard practices, switching to novel hormonal agents has been shown to be much less effective.

Our work with prostate cancer treating clinicians

Click to enlarge

Our work with prostate cancer treating clinicians (see slide for details of our track record and robust prostate cancer treating community) suggests that there will be some significant resistance to change treatment paradigms by cancer treaters especially amongst urologists. In past studies, cancer treaters were less likely to use chemotherapy due to perceived side effects and more likely to use novel hormonal agents despite the lack of supporting evidence especially in older patients. What is your take on the new data presented at ESMO 2019? Let’s set-up a call to further discuss.

Beyond prostate cancer, we offer rich experience, expertise and robust treaters and experts access in all solid, hematological & rare cancers.

Meet us

Let’s take your next step together by arranging a meeting at your offices to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.

Driving impactful outcomes through precision intelligence

MDoutlook empowers confident business decisions with valuable precision insights and actionable intelligence.

At the recent 2019 annual meeting of the Association of Residents in Radiation Oncology (ASTRO), one of our clients was interested in recruiting very specific radiation oncologists (recruited to a very tight inclusion criteria) to an event at the congress to gain a richer understanding of their practices in a number of different tumor-areas and to collect real-world evidence (RWE). The interactive workshops proved highly successful and delivered a better understanding of the current practices of radiation-oncologists across indications to create value across functions (marketing, market access, and medical affairs).

We address client challenges across the product lifecycle and different business functions. During the conference season, for example, we are particularly busy helping clients gain valuable insight into their data presentations as well as measuring impact as can be seen from post-ASCO articles (clinical impact of ASCO presentations covering integration-of-new-treatment-regimens-in-CLL; novel-targeted-agents-for-MNSCLC and what-will-happen-in-NMCRPC and MHSPC.) published in partnership with OBR earlier this Summer.

MDoutlook drives maximizing the opportunity

We specialize in:

  • Connecting clients to the right treaters and experts through our validated community of 120,000 + treaters and 12,000+ experts.
  • Answering today’s critical business questions tomorrow via ONCpulse, our agile, adaptable and technology-driven solution.
  • Experience and expertise of our team that has won client praise and high satisfaction through offering hyper-personalized and impactful solutions.

Meet us

Let’s take your next step together by arranging a meeting at your offices to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1 404.496.4136.

Measuring value perceptions of Immunotherapy

ImmunoOncology (IO) expands the treatment possibilities and provides substantial clinical benefit, especially in patients who had little to no effective treatment options less than a decade ago. IO features prominently at the 2019 annual European Society for Medical Oncology (ESMO) annual congress in Barcelona where agenda items will cover topics such as the current biomarkers in immunotherapy (e.g. PD-L1) and understanding the emerging role of I/O in gastro enterological (GI) cancers.

While IO therapies are among the most promising drugs they are associated with high cost.

Value of medicines number one concern for oncologists.

Where oncologists want pharma to focus their efforts in the next three years

Click on image to enlarge

Financial impact and affordability of medicines are the number one concern for oncologists reported in MDoutlook’s 2019 Leadership research in ImmunoOncology. Oncologists were asked to choose their top three areas (from fourteen attributes) for corporate leaders to improve most in the next three years.

Most Wanted Areas of Improvement for Corporate Leaders in ImmunoOncology - Financial impact

Click on image to enlarge

The sentiment was especially pronounced with US based oncologists where almost half (47%) worry about the financial impact of oncology medications on the healthcare system and patients. In Europe, similar concerns are also shared by a large group of oncologists (37%), and equally viewed as the most concerning aspects moving forward. This coincides with the debate on the value of medicines picking up speed on both continents, and in Europe, more regulators and payors are working together on joint HTA assessments and cross-border purchasing (e.g. BeNeLuxA initiative).

While financial considerations do not materially influence oncologists treatment decisions, the rising cost of medications is an ever-present worry. The surveyed oncologists fear insufficient value may have a toxic financial effect on the overall healthcare system.

Earlier and accelerated access

Oncologists in our research would like to see better and earlier access to innovative treatments for their patients.  Financial support mechanisms such as patient support programs play an important role in making a difference for patients. Aligning your market access programs and strategies with the needs of healthcare professionals will further help to alleviate widely held concerns of “financial toxicity”. Communications and marketing functions also need to improve their messages and materials to communicate enhanced and differentiated value (see our analysis above) for all stakeholders in the healthcare system.

Meet us at ESMO

With IO presentations featuring prominently at major conferences (such as ESMO), it is vital to be in tune with treaters and experts views and have access to timely precision intelligence and actionable recommendations in order to adapt your engagement with your professional audience. Our international teams are uniquely positioned to provide you with vital ingredients of experience, expertise, treaters & ThougthLeader engagement and agile solutions to empower client confidence when guiding commercial strategies.

With wide ranging solutions such as ONCpulse™, we can rapidly access verified and highly relevant oncologists and experts specific to any solid, liquid or rare cancer to capture their views through our large international community.

Let’s take your next step together by meeting at the ESMO annual meeting (September 27 – October 1st) in Barcelona or arranging a more convenient date / time to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1 404.496.4136.

KPI Measurement Success

In today’s climate, the imperative for new products or brands to achieve their full potential quickly has never been greater. Key to achieving success is measuring and communicating progress, both internally and externally. Tracking your product is an iterative process of measuring, managing and monitoring key performance indicators (KPIs) for the market, your product, your competitors.

At MDoutlook, we empower clients with timely precision insights and give confidence in navigating brands successfully in unforgiving markets.

  • Through our key assets we address each brands unique and critical KPIs by targeting the right contacts at the right time in order to furnish clients with rapid, robust and reliable intelligence.
  • Triangulating specific information from KPI tracking research, ATU (Awareness, Trial and Usage) research and other pertinent sources, MDoutlook’s experienced medical and business teams add significant value through timely insights and directly actionable recommendations to drive success!

Improve your commercial strategy

Drawing from our large and validated database of over 120,000 treaters and ThoughtLeaders (TL) in oncology, we identified for one of our clients the root cause of their lack of market share and performed an analysis of 8 key EU markets. We were able to deliver profound customer insights that changed our client’s strategy.

Our client, an international pharmaceutical company, was faced with a dilemma in that one of their brands was not performing well against KPIs, and their market share was stagnant shortly after launch. While there were KPI assessments in place, the client lacked deep customer insights. By exploring and triangulating relevant aspects of KPI, ATU, key account analysis and ThoughtLeader research we gained superior insights (such as measuring message impact; assessing brand uptake; understanding prescribing drivers and barriers; tracking switching patterns and competitive activity over time) that aided our client to change their brand strategy, and their market share tripled in 18 months!

Our KPI measurement approach contributed to our client generating north of €100m in additional sales by continuing to hone their strategies and tactics at both European and country levels!

KPI excellence delivering results!

Utilizing our services, we enable clients to gain a deep understanding of each brand’s unique value proposition. We take a 360-degrees approach (triangulating the right specific and impact information) to understand the barriers and enablers that impact your business.

A critical foundation to our success in tracking KPIs is developing base measurements and planning for uninterrupted performance monitoring to inform confident commercialization decisions.

A critical foundation to our success in tracking KPIs is developing base measurements and planning for uninterrupted performance monitoring to inform confident commercialization decisions.

Engaging our core agile and adaptive services helps MDoutlook deliver actionable KPI precision intelligence and directly actionable recommendations.

  • Rapid results: Timing is everything! We deliver full KPI studies in less than 10 weeks.
  • Right targets: With access to engaged verified, high-quality treaters and experts are we able to reach the speciality physicians key to success.
  • Reach: Access more than 120,000 cancer treaters targeting all tumor and sub-types; ability to reach up to 1 million speciality treaters globally.
  • Robust platform: Adaptable, agile and efficient to cover KPI measurements internationally through MDoutlook proprietary assets.
  • Relevance: Team experience and expertise to guide, customize and drive KPI measurement success with impactful insight and recommendations.

Let´s discuss how we can contribute to your brand’s success through our excellence in KPI measurement. Contact us today at [email protected] or call at +1 404.496.4136 to take the next step.

We will be at the ESMO annual meeting (27 September – 1 October) in Barcelona and look forward to welcoming you there.

Identify rising stars amongst ThoughtLeaders

Increasingly, biopharmaceutical companies recognize the importance and value of identifying and engaging ‘rising stars’ since they are typically younger, tech-engaged, offer novel perspectives, future ThoughtLeaders and a window to tomorrow’s healthcare market.

Similarly, clients are increasingly using MDoutlook precision intelligence to identify the most relevant rising star ThoughtLeaders (TL; also known as KOLs, External Experts, or Therapy Experts) for their interactions and commercialization activities.

Whilst the top TLs are well recognized, identifying rising star TLs is much more challenging. We lighten this process for our clients by providing unparalleled access to over 12,000 validated TLs and well over 120,000 qualified treaters in oncology.

Finding Rising Stars

Rising stars are evolving experts in their therapy area and scientific field, committed to enhancing clinical research and building their scientific footprint and reputation. Our easy-to-use database with advanced analytics and data visualization, identifies rising stars and generates short lists for client use on a scheduled basis.

MDoutlook Tiering of ThoughtLeaders

Click to enlarge

By utilizing machine learning and artificial intelligence to track physician activity in multiple research domains on dozens of data points, and across our defined TL hierarchy, rising stars typically populate Tiers 2 and 3 within our definition. Additionally, this is also the level where peer nominations – the voice of their community – can provide an early indication of upward momentum.

We regularly work with clients at and around medical congresses enriching and enhancing their TL engagement strategies at these pivotal events. In a recent project, we identified rising stars in acute myeloid leukemia (AML) to support our client’s commercialization activities and targeting of this valuable group.

Rising stars within AML ThoughtLeaders

Click to enlarge

Value of Engaging Rising Stars

Our insights conclude that rising star TLs are an imperative to any biopharmaceutical company integrated TL strategy since they represent:

  • Future TLs for future healthcare solutions
  • Engagement opportunities to build relationships now (whilst building their reputation) before the demand for them becomes too strong
  • Often higher patient volumes and strong eagerness to participate in clinical trials
  • Novel perspectives and openness to new approaches for innovative clinical project opportunities
  • More engaged customer embracing digital communication solutions
  • Reference point for future networks with younger oncologists
  • Greater interest in patient-centricity, real-world data application and utilization of tech such as wearable devices.

Precision insight and engagement targeted to all your ThoughtLeader activities

Whether you are engaging with ThoughtLeaders digitally, personally or on the phone, we support you on your knowledge journey. We provide expert insights and ThoughtLeader identification that will make your advisory councils, expert calls, congresses, and virtual engagements a success! At MDoutlook, we help clients to leverage ThoughtLeaders throughout the commercialization lifecycle of a compound and maximize both opportunities and revenues.

We are passionate about our precision intelligence offering and provide you with rapid and actionable answers to all your business questions. All our solutions are scalable to fit your needs & budgets, including integration with legacy systems.

MDoutlook at ASCO 2019

We will be at the ESMO annual meeting (27 September – 1 October) in Barcelona and look forward to welcoming you there.

For further discussion on this or other topics, and to arrange a meeting at your convenience, please contact [email protected] or call +1 404.496.4136.

Rapid insights on clinical impact of ASCO – Integration of new treatment regimens in CLL

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 3rd OncoPoll™ study following the 2019 ASCO conference, we looked at the oral presentations in CLL and researched how US and EU5 oncologists evaluated them.

Click to enlarge

Even with these CLL presentations being on the last day of ASCO, the awareness and enthusiasm for the use of Venetoclax + Obinutuzumab, Acalabrutinib + Obinutuzumab, and the CD19-targeted CAR-T cell product Lisocabtagene Maraleucel does not seem to be dampened. In our full report, we examine how the efficacy and safety & tolerability profiles of each of these agents are viewed in relation to currently available treatment options and how these regimens will be integrated into clinical practice. As can be seen from the data excerpt, there is good reason to assume that the new regimens will be making quite an impact throughout the treatment process.

Click here to get a full copy of our complimentary MDoutlook OncoPoll report

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community – read our blog on this topic on their site.

Last week, we published our post-ASCO OncoPolls on early advanced prostate cancer (nmCRPC and mHSPC) and on novel targeted agents in mNSCLC.

If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.

Rapid insights on clinical impact of ASCO – Novel Targeted Agents for mNSCLC

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 2nd OncoPoll™ study following the 2019 ASCO conference, we researched what US and EU5 oncologists thought about a number of new agents being developed that target specific driver mutations in small populations of metastatic NSCLC patients (among other cancer types).

Click to enlarge

The awareness of these agents is already at a moderate level, higher than what one would normally expect for agents only in Phase 1 and/or Phase 2 clinical trials and broader than just the 40% of respondents who attended the Oral Abstract session at ASCO (see below). In our full report, we examine how the efficacy and safety & tolerability profiles of each of these agents are viewed in relation to currently available treatment options and even dive a little into how these agents are currently compared with each other.

Click here to get a full copy of our complimentary MDoutlook OncoPoll report.

Click to enlarge

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community – read our blog on this topic on their site. We just published our post-ASCO OncoPoll on prostate cancer and our 3rd post-ASCO reports on CLL will be available very soon.

If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.

Rapid insights on clinical impact of ASCO – What will happen in nmCRPC and mHSPC

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. At the 2019 ASCO conference, prostate cancer was one of the hottest areas, and our 1st independent OncoPoll™ study researched how clinicians will be treating the non-metastatic castration-resistant and the metastatic hormone-sensitive prostate cancer (nmCRPC and mHSPC) populations based on the new data presented. The impact of ASCO is far and wide, so in this analysis, we compared how oncologists and urologists in the US and EU5 will be integrating the information into their clinical practices.

post ASCO nmCRPC mHSPC clinical insights MDoutlook

Click to enlarge

All 3 of the 2nd generation anti-androgens discussed during ASCO are seen as more efficacious than currently available treatment options (see figure). But how does this evaluation differ between oncologists and urologists in the US and EU5? Does this positive view extend to the safety profiles? Most importantly, how will these views translate into actual clinical decisions?

Click here to get a full copy of our complimentary MDoutlook OncoPoll report.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community –read our blog on this topic on their site. Be on the lookout for our additional post-ASCO reports on CLL and NSCLC coming soon.

If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.

Redefining engagement with ThoughtLeaders

Identifying the right expert at the right time is often a challenge for many life sciences companies and their agencies. What if there would be a short-cut (with no compromises!) to gain precision engagement with ThoughtLeaders and related treaters? At MDoutlook, we help you tap into the expertise of over 12,000 oncology ThoughtLeaders and 110,000 qualified oncology treaters from over 120 countries.

Precision ThoughtLeader identification and mapping

ThoughtLeader Professional Network - NeuroEndocrine Tumors

Click to enlarge

Our intuitive dashboard gives clients direct access to our MDoutlook ThoughtLeader Attribute Dial™. Driven by our propriety technology and transparent algorithms, clients can manipulate the information to get access to different data sets and results based on changing inputs to match their business needs.

Our unique peer nomination process is further helping clients to identify ThoughtLeaders that are highly regarded by their peers, especially those with more influences or those beyond the top 50. Obtaining this information is easy, and our dashboard enables clients to have all information in one place at their fingertips.

Patient Volume in Select GI Cancers - ThoughtLeaders vs Community

Click to enlarge

Our infographics allow clients to spot connections between different ThoughtLeaders and uncover early adopters for specific cancer treatments. This is particularly impactful when estimating treatment volumes and identify high-volume treaters for a specific cancer.

For one of our clients, we performed an analysis of nearly 1,300 U.S. physician-reported patient volumes in specific GI tumor types, leading to interesting insights. Academic ThoughtLeaders, on average, saw 20% more patients than other community-based ThoughtLeaders.
This also settles an often-asked question if they are too busy in their expert activities to see patients!

Providing support for all your activities

Whether you are engaging with ThoughtLeaders digitally, personally or on the phone, we support you on your knowledge journey. We provide expert insights and ThoughtLeader identification that will make your advisory councils, expert calls, congresses, and virtual engagements a success! At MDoutlook, we help clients to leverage ThoughtLeaders throughout the commercialization lifecycle of a compound and maximize both opportunities and revenues.

We are passionate about our precision intelligence offering and provide you with rapid and actionable answers to all your business questions. All our solutions are scalable to fit your needs & budgets, including integration with legacy systems.

Let´s discuss how to make your ThoughtLeader engagements more targeted by utilizing our precision insights. Contact us today at [email protected] or call at +1 404.496.4136 to find out how we can help you to make the most of your ThoughtLeader interactions.